Journal
NATURE CANCER
Volume 3, Issue 5, Pages 581-+Publisher
NATURE PORTFOLIO
DOI: 10.1038/s43018-022-00344-7
Keywords
-
Categories
Funding
- Care for Carcinoid Foundation Research Grant
- Neuroendocrine Tumor Research Foundation Accelerator Grant
Ask authors/readers for more resources
Hua and colleagues have developed CAR T cells targeting CDH17 and demonstrated their effectiveness in suppressing tumor growth in mouse and human models of neuroendocrine and gastrointestinal solid tumors, without causing damage to healthy tissues in preclinical models.
Gastrointestinal cancers (GICs) and neuroendocrine tumors (NETs) are often refractory to therapy after metastasis. Adoptive cell therapy using chimeric antigen receptor (CAR) T cells, though remarkably efficacious for treating leukemia, is yet to be developed for solid tumors such as GICs and NETs. Here we isolated a llama-derived nanobody, VHH1, and found that it bound cell surface adhesion protein CDH17 upregulated in GICs and NETs. VHH1-CAR T cells (CDH17CARTs) killed both human and mouse tumor cells in a CDH17-dependent manner. CDH17CARTs eradicated CDH17-expressing NETs and gastric, pancreatic and colorectal cancers in either tumor xenograft or autochthonous mouse models. Notably, CDH17CARTs do not attack normal intestinal epithelial cells, which also express CDH17, to cause toxicity, likely because CDH17 is localized only at the tight junction between normal intestinal epithelial cells. Thus, CDH17 represents a class of previously unappreciated tumor-associated antigens that is 'masked' in healthy tissues from attack by CAR T cells for developing safer cancer immunotherapy. Hua and colleagues develop CAR T cells targeting CDH17 and show that they are effective at suppressing tumor growth in mouse and human models of neuroendocrine and gastrointestinal solid tumors, without damaging healthy tissues in preclinical models.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available